AJ Garber, JE Foley, MA Banerji, P Ebeling, … - Diabetes Obes …, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 37 - Related articles - All 4 versions
J Rosenstock, JE Foley, M Rendell, M Landin- … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A 12-week, double-blind, randomized, parallel-group
study comparing vildagliptin (50 mg qd) and placebo was conducted in 179 subjects with IGT
(2-h glucose 9.1 mmol/l, A1C 5.9%). Plasma levels of intact glucagon-like peptide 1 ... Cited by 28 - Related articles - BL Direct - All 5 versions
- ►insulinjournal.com [PDF] B Ahrén - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition
prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active
GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby ... Cited by 26 - Related articles - All 19 versions
- ►endojournals.org K Azuma, Z Radikova, J Mancino, FGS Toledo, … - Journal of Clinical …, 2008 - Endocrine Soc Objective: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin
prolongs the action of endogenously secreted incretin hormones leading to improved glycemic
control in patients with type 2 diabetes mellitus (T2DM). We undertook a double-blinded, ... Cited by 24 - Related articles - BL Direct - All 4 versions
- ►endojournals.org CW Chia, JM Egan - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year follow-up data
on exenatide showed a sustained weight loss and glycosylated hemoglobin (HbA 1c ) reduction
of 1%. Nausea and vomiting are common. Results from phase 3 studies are pending on ... Cited by 24 - Related articles - All 5 versions
- ►diabetesjournals.org E Muscelli, A Mari, A Casolaro, S Camastra, G Seghieri … - Diabetes, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Isoglycemic oral (75 g) and intravenous glucose administration
was performed in 51 subjects (24 with normal glucose tolerance [NGT], 17 with impaired glucose
tolerance [IGT], and 10 with type 2 diabetes) with a wide range of BMI (20–61 kg/m 2 ). C- ... Cited by 19 - Related articles - BL Direct - All 10 versions
RE Pratley, J Rosenstock, FX Pi-Sunyer, MA … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—Mean baseline A1C and fasting plasma glucose (FPG) were significantly lower in
older (70 years: 8.3 ± 0.1% and 9.6 ± 0.1 mmol/l, respectively) than in younger (50 years: 8.7
± 0.0% and 10.5 ± 0.1 mmol/l, respectively) patients. Despite this, the adjusted mean ... Cited by 20 - Related articles - BL Direct - All 5 versions
- ►endojournals.org A Mari, WA Scherbaum, PM Nilsson, G Lalanne, … - Journal of Clinical …, 2008 - Endocrine Soc Design: A 52-wk double-blind, randomized, parallel-group study comparing vildagliptin (50 mg
every day) and placebo was conducted in 306 patients with mild hyperglycemia (glycosylated
hemoglobin of 6.2–7.5%). Plasma glucose and C-peptide levels were measured during ... Cited by 19 - Related articles - BL Direct - All 4 versions
R Christopher, P Covington, M Davenport, P Fleck, QA … - Clinical Therapeutics, 2008 - Elsevier Results: Thirty-six subjects (66 per cohort) were enrolled and completed the study (29/36
[81% ] white; mean age, 26.6 years; mean weight, 76.00 kg)..Alogliptin was rapidly absorbed
(median T max , 1-2 hours) and eliminated slowly (mean t 1/2 , 12.4-21.4 hours), primarily ... Cited by 17 - Related articles - All 2 versions
- ►diabetesjournals.org BJ Lamont, DJ Drucker - Diabetes, 2008 - Am Diabetes Assoc RESULTS AND CONCLUSIONS— Mice treated with vehicle alone or DA-GIP exhibited progressive
weight gain, whereas treatment with Ex-4 or DPP-4i prevented weight gain. Although Ex-4 improved
oral glucose tolerance and insulin-to-glucose ratios after an intraperitoneal glucose ... Cited by 17 - Related articles - BL Direct - All 5 versions
